Text Size

Plasma Brain Natriuretic Peptide Levels in Pregnancy

This study has been completed.
Sponsor:
Information provided by:
Oklahoma State University Center for Health Sciences
ClinicalTrials.gov Identifier:
NCT00324402
First received: May 9, 2006
Last updated: July 8, 2008
Last verified: July 2008
History of Changes
  Purpose

To evaluate the maternal blood concentrations of brain natriuretic peptide (BNP) during the second and third trimesters of a normal pregnancy. We will attempt to define a normal range for pregnancy and any outliers that may serve as markers for abnormal cardiovascular physiology.


Condition
Cardiomyopathy
Pregnancy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Plasma Brain Natriuretic Peptide Levels in Pregnancy

Resource links provided by NLM:

MedlinePlus related topics: Cardiomyopathy
Drug Information available for: Nesiritide
U.S. FDA Resources

Further study details as provided by Oklahoma State University Center for Health Sciences:

Estimated Enrollment: 50
Study Start Date: August 2006
Study Completion Date: June 2008
Groups/Cohorts
1
Healthy pregnant women, 18-40

Detailed Description:

The brain natriuretic peptide (BNP) is a useful marker for volume overload, increased filling pressures and stretching of the myocardium. The current literature contains limited and unreliable information regarding normal BNP values in pregnancy. After baseline echocardiogram to detect individuals with asymptomatic structural defects, the participants will submit to 3 blood draws during the second and third trimester and at delivery to determine normal pregnancy values.

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Healthy pregnant women, 18-40

Criteria

Inclusion Criteria:

  • women age 18 to 40
  • second trimester of pregnancy

Exclusion Criteria:

  • known cardiac or valvular disease,
  • atrial fibrillation or other arrhythmia,
  • pulmonary hypertension,
  • chronic hypertension,
  • hypertensive disorders of pregnancy,
  • morbid obesity (BMI > 40 kg/meter squared)
  • history of sleep apnea
  • multiple gestation
  • known renal dysfunction
  • medications known to affect cardiac function
  • current or past abnormal echocardiogram
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00324402

Locations
United States, Oklahoma
Oklahoma State University Center for Health Sciences
Tulsa, Oklahoma, United States, 74127
Sponsors and Collaborators
Oklahoma State University Center for Health Sciences
Investigators
Study Chair: Kimberly A Sorensen, DO Oklahoma State University Center for Health Sciences
Principal Investigator: John M Beal, DO Oklahoma State University Center for Health Sciences
  More Information

No publications provided

Responsible Party: Dr. J. Martin Beal, assistant professor of Ob/Gyn, Oklahoma State University Center for Health Sciences
ClinicalTrials.gov Identifier: NCT00324402     History of Changes
Other Study ID Numbers: 2005008
Study First Received: May 9, 2006
Last Updated: July 8, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by Oklahoma State University Center for Health Sciences:
brain natriuretic peptide
pregnancy
biomarker

Additional relevant MeSH terms:
Cardiomyopathies
Heart Diseases
Cardiovascular Diseases
Natriuretic Peptide, Brain
Natriuretic Agents
 Physiological Effects of Drugs
Pharmacologic Actions
Cardiovascular Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 16, 2013